SCHEMBL3816675

SCHEMBL3816675

CCOC(=O)c1cn(CC)c2ccc(SCCNC(=O)OC(C)(C)C)cc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
HPGD P15428 4/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK1 P28482 1/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3811662 0.95 LMNA (0.52) LMNAHPGDKMT2AMEN1MAPT
Formic Acid SCHEMBL4392627 0.93 LMNA (0.49) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL3815910 0.91 LMNA (0.49) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL5471995 0.90 LMNA (0.42) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL3983514 0.89 ALDH1A1 (0.51) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL3983498 0.89 ALDH1A1 (0.51) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL3983501 0.88 LMNA (0.42) LMNAHPGDKMT2AMEN1POLB
SCHEMBL3289243 0.88 LMNA (0.40) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL3816031 0.85 LMNA (0.51) LMNAHPGDKMT2AMEN1MAPT
SCHEMBL4396358 0.85 ALDH1A1 (0.48) LMNAHPGDKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756135-B1 ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS GLAXOSMITHKLINE ZAGREB (HR) 2009-08-12 EP disclosed
US-7569550-B2 14 and 15 membered ring compounds GLAXO GROUP LIMITED (GB) 2009-08-04 US disclosed
US-20080255060-A1 Ester Linked Macrolides Useful For The Treatment of Microbial Infections GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) 2008-10-16 US disclosed
US-20070213283-A1 Macrolides substituted at the 4\"-position GLAXO GROUP LIMITED (GB) 2007-09-13 US disclosed
US-20070185117-A1 Novel 14 and 15 membrered ring compounds GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
EP-1628988-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185117-A1 Novel 14 and 15 membrered ring compounds CYP51A1, LSS, IL17A LMNA 2615/4885HPGD 1267/4885KMT2A 4774/4885
US-20080255060-A1 Ester Linked Macrolides Useful For The Treatment of Microbial Infections CYP51A1, TLR5, MALT1 LMNA 2596/4885HPGD 1842/4885KMT2A 4129/4885
US-20070213283-A1 Macrolides substituted at the 4\"-position IL4, CYP51A1, IL17A LMNA 2144/4885HPGD 2689/4885KMT2A 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.